Tag: $Bristol Myers

Bristol Myers Squibb (BMY) rose Thursday on the back of better-than-expected fourth-quarter earnings but most encouraging was an upbeat outlook from the drugmaker.

Drugmaker Bristol Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to diversify from legacy products facing competition from generic drugs.

A drug trial failure this spring has had no impact on the market for one of Bristol Myers Squibb’s (BMY) most closely-watched new medicines, the company’s chief commercialization officer, Adam Lenkowsky, told Barron’s ahead of the company’s earnings release Thursday.

Bristol Myers Squibb has signed a partnership worth up to $11bn to develop a BioNTech cancer drug that has the potential to beat the world’s bestselling medicine Keytruda.

Bristol Myers Squibb reported better-than-expected earnings for the first quarter and boosted its outlook while noting the impact of stiff competition in the pharmaceutical market.

Bristol Myers Squibb’s Cobenfy as an adjunctive treatment did not reach the threshold for a statistically significant difference compared to a placebo with an atypical antipsychotic in adults with schizophrenia.

Bristol Myers Squibb on Thursday said it will slash $2 billion in costs by the end of 2027, expanding its ongoing cost savings effort to chart a path toward long-term growth.

Bristol Myers Squibb on Thursday reported third-quarter earnings and revenue that blew past Wall Street’s expectations thanks to its blockbuster blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term growth.

The Food and Drug Administration on Thursday approved Bristol Myers Squibb’s highly anticipated schizophrenia drug Cobenfy, the first novel type of treatment for the debilitating, chronic mental disorder in more than seven decades.

 Drugmaker Bristol Myers Squibb posted better-than-expected second-quarter results, driven by growth from new products like anemia treatment Reblozyl and heart drug Camzyos as well as from its top-seller, blood thinner Eliquis.

 Drugmaker Bristol Myers Squibb said it has signed a $380 million deal with contract manufacturer Cellares to manufacture its CAR-T cell therapies in the United States, EU and Japan.

Bristol Myers Squibb will acquire radiopharmaceutical therapeutics company RayzeBio for $62.50 a share in cash.

 Bristol Myers Squibb  on Friday agreed to buy Karuna Therapeutics for $14 billion, gaining a promising experimental schizophrenia drug to help power growth as patents on its older therapies expire later this decade.

Bristol-Myers Squibb on Sunday said it will acquire cancer drugmaker Mirati Therapeutics for up to $5.8 billion, diversifying its oncology business and adding drugs it hopes can help offset expected lost revenue from patent expirations later this decade.